Term of Royalty Obligations. The Royalties specified in Section 2.1 shall commence on the Effective Date, and shall continue, in each country on a product-by-product and country-by-country basis until the later of i) the date of expiration of the last to expire patent included within the Innovation, or ii) the date of expiration of the last strategic partnership/licensing agreement including the Innovation.
Appears in 3 contracts
Samples: Confirmatory Patent Assignment and Royalty Agreement (Mira Pharmaceuticals, Inc.), Patent Assignment and Royalty Agreement (MyMD Pharmaceuticals, Inc.), Patent Assignment and Royalty Agreement (MyMD Pharmaceuticals, Inc.)
Term of Royalty Obligations. The Royalties specified in Section 2.1 shall commence on the Effective Date, and shall continue, in each country on a product-by-product and country-by-country basis until the later of i) the date of expiration of the last to expire patent included within the Innovationcovering a Licensed Product, or ii) the date of expiration of the last strategic partnership/licensing sublicensing agreement including the Innovationcovering a Licensed Product (“Term”).
Appears in 1 contract
Samples: Exclusive License Agreement (Telomir Pharmaceuticals, Inc.)
Term of Royalty Obligations. The Royalties specified in Section 2.1 2.2 shall commence on the Effective Date, and shall continue, in each applicable country on a product-by-product and country-by-country basis until the later of i) the date of expiration of the last to expire patent included within the Innovation, or ii) the date of expiration of the last strategic partnership/licensing agreement including the InnovationPatent Rights(“Term”).
Appears in 1 contract
Samples: Exclusive License Agreement (Mira Pharmaceuticals, Inc.)
